What they were paid
ALNYLAM PHARMACEUTICALS Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $0 | $0 | $0 | $0 | $0 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALNYLAM PHARMACEUTICALS, INC. DEF 14A filed April 6, 2026, accession 0001628280-26-023923, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025ALNYLAM PHARMACEUTICALS pays directors a $60,000 cash retainer and $400,000 in equity.
Committees
FY2025 · as the proxy prints themScience and Technology
The rest of the ALNYLAM PHARMACEUTICALS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Amy W. Schulman | Chair of the Board | $541,310 |
| Colleen F. Reitan | Independent Director | $492,350 |
| David E.I. Pyott | Independent Director | $479,850 |
| Dennis A. Ausiello, M.D | Independent Director | $479,850 |
| Elliott Sigal, M.D., Ph.D | Independent Director | $486,310 |
| Margaret A. Hamburg, M.D | Independent Director | $469,850 |
| Olivier Brandicourt, M.D | Independent Director | $482,350 |
| Peter N. Kellogg | Independent Director | $484,850 |
| Yvonne L. Greenstreet, M.D | Director | $0 |
The full ALNYLAM PHARMACEUTICALS compensation record
free company briefThis page is one director within ALNYLAM PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat